[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2883000B1 - Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique - Google Patents

Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique

Info

Publication number
FR2883000B1
FR2883000B1 FR0502479A FR0502479A FR2883000B1 FR 2883000 B1 FR2883000 B1 FR 2883000B1 FR 0502479 A FR0502479 A FR 0502479A FR 0502479 A FR0502479 A FR 0502479A FR 2883000 B1 FR2883000 B1 FR 2883000B1
Authority
FR
France
Prior art keywords
therapeutics
trifluoromethylbenzamide
derivatives
trifluoromethylbenzamide derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0502479A
Other languages
English (en)
Other versions
FR2883000A1 (fr
Inventor
Bruno Roux
Isabelle Berard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0502479A priority Critical patent/FR2883000B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to CA2600904A priority patent/CA2600904C/fr
Priority to ES06706976T priority patent/ES2317496T3/es
Priority to PCT/EP2006/001374 priority patent/WO2006097169A1/fr
Priority to JP2008501173A priority patent/JP5042987B2/ja
Priority to AU2006224853A priority patent/AU2006224853B2/en
Priority to EP06706976A priority patent/EP1858867B1/fr
Priority to US11/908,712 priority patent/US7947675B2/en
Priority to AT06706976T priority patent/ATE420081T1/de
Priority to DE602006004713T priority patent/DE602006004713D1/de
Priority to ARP060100959A priority patent/AR053340A1/es
Publication of FR2883000A1 publication Critical patent/FR2883000A1/fr
Application granted granted Critical
Publication of FR2883000B1 publication Critical patent/FR2883000B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR0502479A 2005-03-14 2005-03-14 Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique Expired - Fee Related FR2883000B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0502479A FR2883000B1 (fr) 2005-03-14 2005-03-14 Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
AT06706976T ATE420081T1 (de) 2005-03-14 2006-02-16 Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
PCT/EP2006/001374 WO2006097169A1 (fr) 2005-03-14 2006-02-16 Derives trifluoromethylbenzamide et leurs utilisations therapeutiques
JP2008501173A JP5042987B2 (ja) 2005-03-14 2006-02-16 トリフルオロメチルベンズアミド誘導体およびその治療上の使用
AU2006224853A AU2006224853B2 (en) 2005-03-14 2006-02-16 Trifluoromethylbenzamide derivatives and therapeutic uses thereof
EP06706976A EP1858867B1 (fr) 2005-03-14 2006-02-16 Derives trifluoromethylbenzamide et leurs utilisations therapeutiques
CA2600904A CA2600904C (fr) 2005-03-14 2006-02-16 Derives trifluoromethylbenzamide et leurs utilisations therapeutiques
ES06706976T ES2317496T3 (es) 2005-03-14 2006-02-16 Derivados del trifluorometilbenzamida y los usos terapeuticos de los mismos.
DE602006004713T DE602006004713D1 (de) 2005-03-14 2006-02-16 Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
US11/908,712 US7947675B2 (en) 2005-03-14 2006-02-16 Trifluoromethylbenzamide derivatives and therapeutic uses thereof
ARP060100959A AR053340A1 (es) 2005-03-14 2006-03-14 Derivados de trifluormetilbenzamida y sus usos terapeuticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502479A FR2883000B1 (fr) 2005-03-14 2005-03-14 Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique

Publications (2)

Publication Number Publication Date
FR2883000A1 FR2883000A1 (fr) 2006-09-15
FR2883000B1 true FR2883000B1 (fr) 2007-06-01

Family

ID=34981603

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502479A Expired - Fee Related FR2883000B1 (fr) 2005-03-14 2005-03-14 Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique

Country Status (11)

Country Link
US (1) US7947675B2 (fr)
EP (1) EP1858867B1 (fr)
JP (1) JP5042987B2 (fr)
AR (1) AR053340A1 (fr)
AT (1) ATE420081T1 (fr)
AU (1) AU2006224853B2 (fr)
CA (1) CA2600904C (fr)
DE (1) DE602006004713D1 (fr)
ES (1) ES2317496T3 (fr)
FR (1) FR2883000B1 (fr)
WO (1) WO2006097169A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
NZ537603A (en) 2002-07-12 2006-09-29 Sanofi Aventis Deutschland Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Also Published As

Publication number Publication date
JP2008537933A (ja) 2008-10-02
EP1858867A1 (fr) 2007-11-28
CA2600904A1 (fr) 2006-09-21
AU2006224853A1 (en) 2006-09-21
JP5042987B2 (ja) 2012-10-03
FR2883000A1 (fr) 2006-09-15
US7947675B2 (en) 2011-05-24
CA2600904C (fr) 2013-12-10
WO2006097169A1 (fr) 2006-09-21
ATE420081T1 (de) 2009-01-15
DE602006004713D1 (de) 2009-02-26
AR053340A1 (es) 2007-05-02
ES2317496T3 (es) 2009-04-16
AU2006224853B2 (en) 2011-08-18
US20080119459A1 (en) 2008-05-22
EP1858867B1 (fr) 2009-01-07

Similar Documents

Publication Publication Date Title
FR2873368B1 (fr) Derives de guanidine et leurs utilisations en therapeutique
CY2017006I1 (el) Αερολυμενες φθοροκινολονες και χρησεις αυτων
CR8037A (es) Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
MA29039B1 (fr) Dibenzylamines et derives
FR2908978B1 (fr) Porte-protheses et leurs applications.
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
ATE540100T1 (de) Verbesserungen bei textilbehandlungsmitteln
IL185034A0 (en) 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics
BRPI0614961A2 (pt) aptâmero, método, e, composição
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
FR2883000B1 (fr) Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
DE602006016400D1 (de) Damit
FR2922209B1 (fr) 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE.
DK2188258T3 (da) Substituerede nikotinamidforbindelser og anvendelser deraf i lægemidler
FR2903106B1 (fr) Utilisations de 2-benzoyl-imidazopyridines en therapeutique
FR2873118B1 (fr) Derives de pyrido-pyrimidine, leur application en therapeutique
HK1134286A1 (en) Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
MA28847B1 (fr) Derives de pyrrole, leur preparation et leur utilisation en therapeutique
NL1029139A1 (nl) Nieuwe aminopyridinederivaten en hun gebruik als farmaceutica.
NO20042050D0 (no) Viskoelastiske dempere i rorsystem
FR2909668B1 (fr) Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique
DOP2007000004A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
FR2883750B1 (fr) Compositions topiques et leurs utilisations

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20141128